Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells

Cancer Research

Volumn 59, Issue 2, 1999, Pages 431-435

  Kawashima, Ichiro ^a   Tsai, Van ^b   Southwood, Scott ^b   Takesako, Kazutoh ^a   Sette, Alessandro ^b   Celis, Esteban ^c  

^a TAKARA SHUZO CO LTD   (Japan)

^b Epimmune   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HLA A3 ANTIGEN; PEPTIDE;

ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN FAMILY; TUMOR CELL LINE;

CARCINOEMBRYONIC ANTIGEN; CELL LINE; CROSS REACTIONS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A3 ANTIGEN; HUMANS; IMMUNIZATION; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033556012     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Zinkernagel, R. M., and Doherty, P. C. The discovery of MHC restriction. Immunol. Today, 18: 14-17, 1997.
2. York, I. A., and Rock, K. L. Antigen processing and presentation by the class I major histocompatibility complex. Annu. Rev. Immunol., 14: 369-396, 1996.
3. Rammensee, H. G., Falk, K., and Rotzschke, O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol., 11: 213-244, 1993.
4. Berke, G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu. Rev. Immunol., 12: 735-773, 1994.
5. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
6. Lindauer, M., Stanislawski, T., Haussler, A., Antunes, E., Cellary, A., Huber, C., and Theobald, M. The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes. J. Mol. Med. (Berl.), 76: 32-47, 1998.
7. Van den Eynde, B. J., and Boon, T. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res., 27: 81-86, 1997.
8. Thompson, J. A., Grunert, F., and Zimmermann, W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal., 5: 344-366, 1991.
9. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor stares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
10. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.), 319: 226-230, 1986.
11. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., and Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (Lond.), 319: 230-234, 1986.
12. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
13. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
14. Borg, A., Tandon, A. K., Sigurdsson, H., Clark, G. M., Ferno, M., Fuqua, S. A., Killander, D., and McGuire, W. L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res., 50: 4332-4337, 1990.
15. Berchuck, A., Rodriguez, G., Kinney, R. B., Soper, J. T., Dodge, R. K., Clarke-Pearson, D. L., and Bast, R. C., Jr. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol., 164: 15-21, 1991.
16. Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R., Rodriguez, G. C., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., Jr., and Berchuck, A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer (Phila.), 73: 2380-2385, 1994.
17. Kuhn, E. J., Kumot, R. A., Sesterhenn, I. A., Chang, E. H., and Moul, J. W. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol., 150: 1427-1433, 1993.
18. Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., and Sasaki, T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res., 51: 1034-1038, 1991.
19. ERBB2 expression and the gene amplification. Cancer Res., 50: 8002-8009, 1990.
20. Houldsworth, J., Cordon-Cardo, C., Ladanyi, M., Kelsen, D. P., and Chaganti, R. S. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res., 50: 6417-6422, 1990.
21. Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Kunz., J., Beger, H. G., and Korc, M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol., 24: 1127-1134, 1993.
22. Weidner, U., Peter, S., Strohmeyer, T., Hussnatter, R., Ackermann, R., and Sies, H. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res., 50: 4504-4509, 1990.
23. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5187, 1990.
24. Rachwal, W. J., Bongiorno, P. F., Orringer, M. B., Whyte, R. I., Ethier, S. P., and Beer, D. G. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br. J. Cancer, 72: 56-64, 1995.
25. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol., 59: 1-14, 1998.
26. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., nd Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
27. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/ neu protooncogene protein. Cancer Res., 54: 1071-1076, 1994.
28. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
29. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
30. Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M. L., Cheever, M. A., and Sherman, L. A. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum. Immunol., 52: 109-118, 1997.
31. Tsai, V., Kawashima, I., Keogh, E., Daly, K., Sette, A., and Celis, E. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit. Rev. Immunol., 18: 65-75, 1998.
32. Sidney, J., Grey, H. M., Southwood, S., Celis, E., Wentworth, P. A., del Guercio, M. F., Kubo, R. T., Chesnut, R. W., and Sette, A. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum. Immunol., 45: 79-93, 1996.
33. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
34. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
35. Storkus, W. J., Zeh, H. J., III, Maeurer, M. J., Salter, R. D., and Lotze, M. T. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol., 151: 3719-3727, 1993.
36. Wentworth, P. A., Celis, E., Crimi, C., Stitely, S., Hale, L., Tsai, V., Serra, H. M., Del Guercio, M. F., Livingston, B., Alazard, D., Fikes, J., Kubo, R. T., Grey, H. M., Chesnut, R. W., Chisari, F. V., and Sette, A. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol. Immunol., 32: 603-612, 1995.
37. + CTLs from naive precursors. J. Immunol., 153: 996-1003, 1994.
38. Okada, C. Y., and Rechsteiner, M. Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell, 29: 33-41, 1982.
39. Riddell, S. R., Elliott, M., Lewinsohn, D. A., Gilbert, M. J., Wilson, L., Manley, S. A., Lupton, S. D., Overall, R. W., Reynolds, T. C., Corey, L., and Greenberg, P. D. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med., 2: 216-223, 1996.
40. Tsai, V., Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., and Celis, E. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158: 1796-1802, 1997.
41. Kawashima, I., Tsai, V., Southwood, S., Takesako, K., Celis, E., and Sette, A. Identification of gp100-derived melanoma specific CTL epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int. J. Cancer. 78: 518-524, 1998.
42. Parker, K. C., Bednarek, M. A., and Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol., 152: 163-175, 1994.
43. Bremers, A. J., van der Burg, S. H., Kuppen, P. J., Kast, W. M., van de Velde, C. J., and Melief, C. J. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. J. Immunother., 18: 77-85, 1995.